LinkedIn cofounder Reid Hoffman said the era of winning with AI chatbots has ended and the next major opportunity is AI-powered medicine [1, 2].
This shift in focus suggests a pivot from consumer-facing generative tools toward high-stakes industrial applications. By targeting drug discovery, AI companies can move from providing general assistance to creating tangible, patent-protected medical breakthroughs.
Speaking this week at the Semafor World Economy Summit 2026 in Washington, D.C., Hoffman said healthcare is a significantly larger market than consumer chatbots [3, 4]. He said the current gold rush for chatbots is fading, while the application of artificial intelligence to medicine represents a new growth frontier [1, 5].
Hoffman, who is also a partner at Greylock, said AI can accelerate the process of drug discovery [2, 5]. He said this transition allows companies to develop innovations that are not only lucrative but also protected by patents, providing a more sustainable business model than the competitive chatbot landscape [1, 5].
The transition toward medical AI reflects a broader trend of seeking "vertical AI" solutions, tools designed for specific professional industries rather than general use. Hoffman said the most significant value now lies in solving complex biological and chemical problems rather than refining conversational interfaces [1, 2].
“The AI chatbot gold rush is over.”
This perspective indicates a maturing AI market where the 'low-hanging fruit' of natural language processing has been harvested. By shifting toward drug discovery, the industry is moving from a service-based model toward a product-based model where value is derived from intellectual property and life-saving medical outcomes rather than user engagement metrics.
